ALKERMES | ALKS - Des Atouts

Prix De L'Action
34.20
Variation Quotidienne
-0.64 -1.84%
Mensuellement
20.21%
Annuel
15.97%
Q2 Prévisions
33.76




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
J&J USD 199.21B 6.39B 2025-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Merck USD 129.55B 12.02B 2025-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Otsuka Holdings JPY 4.2T 238.02B 2025-12
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pfizer USD 208.73B 2.64B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12